---
title: "Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295446054.md"
description: "The Phase 1/1b CLARITY-101 clinical trial has been launched to study DMR-001 in individuals suffering from mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This trial aims to assess the effectiveness and safety of DMR-001 in treating these conditions."
datetime: "2026-08-10T20:07:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295446054.md)
  - [en](https://longbridge.com/en/news/295446054.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295446054.md)
generator: "portal-rs"
---

# Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

The Phase 1/1b CLARITY-101 clinical trial has been launched to study DMR-001 in individuals suffering from mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This trial aims to assess the effectiveness and safety of DMR-001 in treating these conditions.

### Related Stocks

- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)

## Related News & Research

- [Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasms](https://longbridge.com/en/news/295448291.md)
- [Damora Therapeutics starts Phase 1/1b CLARITY-101 trial of DMR-001 in mutant CALR-driven ET, myelofibrosis](https://longbridge.com/en/news/294963179.md)
- [Active Biotech wins European regulatory approval to resume tasquinimod myelofibrosis trial enrollment](https://longbridge.com/en/news/296500289.md)
- [Gentian Diagnostics hosts webinar on circulating calprotectin use in rheumatic disease management](https://longbridge.com/en/news/296439040.md)
- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**